1. Home
  2. UWMC vs MNPR Comparison

UWMC vs MNPR Comparison

Compare UWMC & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UWM Holdings Corporation

UWMC

UWM Holdings Corporation

HOLD

Current Price

$1.83

Market Cap

719.2M

Sector

Finance

ML Signal

HOLD

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$109.13

Market Cap

587.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UWMC
MNPR
Founded
1986
2014
Country
United States
United States
Employees
9100
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
719.2M
587.4M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
UWMC
MNPR
Price
$1.83
$109.13
Analyst Decision
Buy
Strong Buy
Analyst Count
10
11
Target Price
$6.13
$107.00
AVG Volume (30 Days)
18.8M
210.1K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
11.53%
N/A
EPS Growth
N/A
54.99
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$16.60
N/A
P/E Ratio
$82.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.72
$29.18
52 Week High
$7.14
$116.64

Technical Indicators

Market Signals
Indicator
UWMC
MNPR
Relative Strength Index (RSI) 32.38 62.67
Support Level N/A $52.92
Resistance Level $2.38 $112.57
Average True Range (ATR) 0.10 8.75
MACD 0.00 -0.80
Stochastic Oscillator 24.74 67.27

Price Performance

Historical Comparison
UWMC
MNPR

About UWMC UWM Holdings Corporation

UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

Share on Social Networks: